Our news journalists obtained a quote from the research from the University of Salerno, "The first choice treatment at all ages is weight loss and/or lifestyle changes, however compliance is very poor and a pharmacological approach has become necessary. In the present article we present a systematic literature review focusing on established pediatric NALFD drugs (ursodeoxycholic acid, insulin sensitizers, and antioxidants) and on innovative therapeutic options as well.Regarding the former ones, a pediatric pilot study highlighted that ursodeoxycholic acid is not efficient on transaminases levels and bright liver. Similarly, a recent large scale, multicenter randomized clinical trial (TONIC study) showed that also insulin sensitizers and antioxidant vitamin E have scarce effects on serum transaminase levels. Among a large series of novel therapeutic approaches acting on recently proposed different pathomechanisms, probiotics seem hitherto the most interesting and reasonable option for their safety and tolerability."
According to the news editors, the research concluded: "Toll-like receptors modifiers, Pentoxifylline, and Farnesoid X receptors agonists have been still poorly investigated, and will need further studies before becoming possible promising innovative therapeutic strategies."
For more information on this research see: Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Italian Journal of Pediatrics, 2012;38():55. (BioMed Central - www.biomedcentral.com/; Italian Journal of Pediatrics - www.ijponline.net)
The news correspondents report that additional information may be obtained from P. Vajro, Chair of Pediatrics, Medical School of the University of Salerno, Salerno, Italy and ELFID, Naples, Italy.
Keywords for this news article include: Italy, Europe, Salerno, Therapy, Pediatrics, Fatty Liver Disease, Alcoholic Fatty Liver, Digestive System Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.